Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves Relypsa’s drug to treat high potassium levels

The U.S. Food and Drug Administration approved Relypsa Inc’s drug to treat potentially fatal levels of potassium in patients with chronic kidney disease or heart problems. The drug, Veltassa, is designed to treat hyperkalemia, a chronic condition characterized by excessive potassium levels in the blood that could lead to dangerous changes in heart rhythm. Relypsa’s […]

Read More »

Mediterranean diet linked to healthier aging brain

(Reuters Health) – Following a Mediterranean diet rich in fruits, vegetables, legumes, whole grains, fish and healthy fats may preserve a more youthful brain in old age, a U.S. study suggests. Previous research has connected a Mediterranean diet to a reduced risk of developing Alzheimer’s disease and other degenerative brain conditions, noted lead study author […]

Read More »

Knee replacement surgery works, but so can nonsurgical techniques

(Reuters Health) – Total knee replacement can usually relieve pain and improve function, but a nonsurgical regimen can also be effective in some people without posing the complication risks that can plague people who choose surgery, according to a new study. The test found that while 85 percent of patients who underwent surgery showed clinically-significant […]

Read More »

Genetics help explain poor showing for GSK malaria vaccine

Scientists have found a genetic explanation for why the world’s first malaria vaccine is not very effective in protecting some African children against the deadly mosquito-borne disease. The analysis, published in the New England Journal of Medicine on Wednesday, comes at a critical time for the experimental shot from GlaxoSmithKline, when global experts are assessing […]

Read More »

FDA staff reviewers question safety of AstraZeneca’s gout drug

Staff reviewers of the U.S. Food and Drug Administration have raised questions about the safety of AstraZeneca Plc’s gout treatment. Reviewers pointed to higher death rates, cardiovascular issues and kidney-related side effects in patients who took the drug, lesinurad, a preliminary review published on Wednesday showed. Industry analysts forecast annual sales of the drug to […]

Read More »

Physicians Interactive Advances Global Health Digital Engagement by Acquiring Univadis

Authoritative Medical Content Platform Combined with Deep Digital Expertise Offers Greater Opportunities to Engage Healthcare Professionals and Improve Outcomes   READING, Mass., Oct. 21, 2015 /PRNewswire/ — Physicians Interactive® (PI) announced today the launch of its recently acquired Univadis platform, the world’s largest healthcare professional (HCP) network. Univadis, previously a wholly-owned subsidiary of Merck (known […]

Read More »

Abbott sales beat as demand for generic drugs rises

Abbott Laboratories Inc (ABT.N) reported better-than-expected quarterly sales as demand rose for its generic drugs in emerging markets, including Latin America and China. Abbott said on Wednesday sales of its generic drugs grew in double digits in emerging markets, helped by the acquisition of Chilean drugmaker CFR Pharmaceuticals SA last year. Sales of generic drugs […]

Read More »

Novartis broadens cancer immune therapy pipeline with acquisition, pacts

Novartis has broadened its immuno-oncology pipeline with the acquisition of Admune Therapeutics and through licensing agreements with small drug developers Xoma and Palobiofarma.   Palobiofarma, a Spanish biotech company, said separately it entered into a $15 million licensing agreement with the Swiss group. Novartis said in a statement on Wednesday these transactions add Admune’s IL-15 […]

Read More »

In Face of Dropping Stocks and Failed Phase III, Biogen Restructures, Slashes Programs and Lays off 880 People

Cambridge, Mass.-based Biogen, Inc. (BIIB) announced today that it was restructuring, cutting 11 percent of its workforce, and slashing programs. In addition, the company announced that its Phase III ASCEND clinical trial of natalizumab for the treatment of secondary progressive multiple sclerosis (SPMS) failed to hit its primary and secondary endpoints. As part of the […]

Read More »

23andMe launches new consumer test service to check for genetic disorders

Genetics company 23andMe announced the launch of a new consumer genetic test service on Wednesday that will show whether an individual carries genes associated with 36 different disorders, such as cystic fibrosis. The launch is a major step for the company, which in 2013 was ordered by the Food and Drug Administration to stop selling […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom